If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-03. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
In geology, hotspots (or hot spots) are volcanic locales thought to be fed by underlying mantle that is anomalously hot compared with the surrounding mantle. Examples include the Hawaii, Iceland, and Yellowstone hotspots. A hotspot's position on the Earth's surface is independent of tectonic plate boundaries, and so hotspots may create a chain of volcanoes as the plates move above them. There are two hypotheses that attempt to explain their origins. One suggests that hotspots are due to mantle plumes that rise as thermal diapirs from the core–mantle boundary. The alternative plate theory is that the mantle source beneath a hotspot is not anomalously hot, rather the crust above is unusually weak or thin, so that lithospheric extension permits the passive rising of melt from shallow depths.
=== Modern scope === Today, neuroendocrinology embraces a wide range of topics that arose directly or indirectly from the core concept of neuroendocrine neurons. Neuroendocrine neurons control the gonads, whose steroids, in turn, influence the brain, as do corticosteroids secreted from the adrenal gland under the influence of adrenocorticotrophic hormone. The study of these feedbacks became the province of neuroendocrinologists. The peptides secreted by hypothalamic neuroendocrine neurons into the blood proved to be released also into the brain, and the central actions often appeared to complement the peripheral actions. So understanding these central actions also became the province of neuroendocrinologists, sometimes even when these peptides cropped up in quite different parts of the brain that appeared to serve functions unrelated to endocrine regulation. Neuroendocrine neurons were discovered in the peripheral nervous system, regulating, for instance, digestion. The cells in the adrenal medulla that release adrenaline and noradrenaline proved to have properties between endocrine cells and neurons, and proved to be outstanding model systems for instance for the study of the molecular mechanisms of exocytosis. And these, too, have become, by extension, neuroendocrine systems. Neuroendocrine systems have been important to our understanding of many basic principles in neuroscience and physiology, for instance, our understanding of stimulus-secretion coupling.
==== Congenital ==== A persistent thyroglossal duct is the most common clinically significant birth defect of the thyroid gland. A persistent sinus tract may remain as a vestigial remnant of the tubular development of the thyroid gland. Parts of this tube may be obliterated, leaving small segments to form thyroglossal cysts. Preterm neonates are at risk of hypothyroidism as their thyroid glands are insufficiently developed to meet their postnatal needs. In order to detect hypothyroidism in newborn babies, to prevent growth and development abnormalities in later life, many countries have newborn screening programs at birth. Infants with thyroid hormone deficiency (congenital hypothyroidism) can manifest problems of physical growth and development as well as brain development, termed cretinism. Children with congenital hypothyroidism are treated supplementally with levothyroxine, which facilitates normal growth and development. Mucinous, clear secretions may collect within these cysts to form either spherical masses or fusiform swellings, rarely larger than 2 to 3 cm in diameter. These are present in the midline of the neck anterior to the trachea. Segments of the duct and cysts that occur high in the neck are lined by stratified squamous epithelium, which is essentially identical to that covering the posterior portion of the tongue in the region of the foramen cecum. The disorders that occur in the lower neck more proximal to the thyroid gland are lined by epithelium resembling the thyroidal acinar epithelium.
Documented from about 1140 onwards, the comital dynasty residing in Tyrol Castle near Meran held the office of Vogts (bailiffs) in the Trent diocese. They extended their territory over much of the region and came to surpass the power of the bishops, who were nominally their feudal lords. After the deposition of the Welf Duke Henry X of Bavaria in 1138, the counts of Tyrol strengthened their independence. When Henry the Lion was again enfeoffed with the Bavarian duchy by Emperor Frederick Barbarossa at the 1154 Imperial Diet in Goslar, his possessions no longer comprised the Tyrolean lands. The counts maintained that independence under the rising Bavarian Wittelsbach dynasty. In 1210, Count Albert IV of Tyrol also took over the Vogt office in the Bishopric of Brixen, prevailing against the rivalling counts of Andechs.
Sources: en.wikipedia.org
The Napoleonic wars also played a key role in the independence of the Latin American colonies from Spain and Portugal. The conflict weakened the authority and military power of Spain, especially after the Battle of Trafalgar. There were many uprisings in Spanish America, leading to the wars of independence. In Portuguese America, Brazil experienced greater autonomy as it now served as seat of the Portuguese Empire and ascended politically to the status of Kingdom. These events also contributed to the Portuguese Liberal Revolution in 1820 and the Independence of Brazil in 1822. The century of relative transatlantic peace, after the Congress of Vienna, enabled the "greatest intercontinental migration in human history" beginning with "a big spurt of immigration after the release of the dam erected by the Napoleonic Wars." Immigration inflows relative to the US population rose to record levels (peaking at 1.6 percent in 1850–1851), as 30 million Europeans relocated to the United States between 1815 and 1914. Another concept emerged from the Congress of Vienna—that of a unified Europe. After his defeat, Napoleon deplored the fact that his dream of a free and peaceful "European association" remained unaccomplished. Such a European association would share the same principles of government, system of measurement, currency and Civil Code. One-and-a-half centuries later, and after two world wars several of these ideals re-emerged in the form of the European Union.
=== MeSH D12.644.456 – oligopeptides === MeSH D12.644.456.050 – amanitins MeSH D12.644.456.073 – angiotensins MeSH D12.644.456.073.021 – angiotensin i MeSH D12.644.456.073.041 – angiotensin ii MeSH D12.644.456.073.041.050 – angiotensin amide MeSH D12.644.456.073.041.800 – saralasin MeSH D12.644.456.073.041.815 – 1-sarcosine-8-isoleucine angiotensin ii MeSH D12.644.456.073.055 – angiotensin iii MeSH D12.644.456.073.070 – angiotensinogen MeSH D12.644.456.120 – antipain MeSH D12.644.456.193 – bradykinin MeSH D12.644.456.193.400 – kallidin MeSH D12.644.456.241 – caerulein MeSH D12.644.456.270 – chalones MeSH D12.644.456.300 – delta sleep-inducing peptide MeSH D12.644.456.345 – dipeptides MeSH D12.644.456.345.159 – anserine MeSH D12.644.456.345.190 – aspartame MeSH D12.644.456.345.331 – carnosine MeSH D12.644.456.345.360 – enalapril MeSH D12.644.456.345.360.300 – enalaprilat MeSH D12.644.456.345.575 – glycylglycine MeSH D12.644.456.345.600 – lisinopril MeSH D12.644.456.400 – n-formylmethionine leucyl-phenylalanine MeSH D12.644.456.448 – glutathione MeSH D12.644.456.448.500 – glutathione disulfide MeSH D12.644.456.448.750 – s-nitrosoglutathione MeSH D12.644.456.460 – gonadorelin MeSH D12.644.456.460.150 – buserelin MeSH D12.644.456.460.315 – goserelin MeSH D12.644.456.460.480 – leuprolide MeSH D12.644.456.460.600 – nafarelin MeSH D12.644.456.460.800 – triptorelin MeSH D12.644.456.580 – leupeptins MeSH D12.644.456.650 – netropsin MeSH D12.644.456.716 – pentagastrin MeSH D12.644.456.724 – pepstatins MeSH D12.644.456.726 – peptichemio MeSH D12.644.456.729 – peptide t MeSH D12.644.456.735 – phalloidine MeSH D12.644.456.745 – thyrotropin-releasing hormone MeSH D12.644.456.800 – tachykinins MeSH D12.644.456.800.354 – eledoisin MeSH D12.644.456.800.475 – kassinin MeSH D12.644.456.800.500 – neurokinin a MeSH D12.644.456.800.550 – neurokinin b MeSH D12.644.456.800.745 – physalaemin MeSH D12.644.456.800.866 – substance p MeSH D12.644.456.805 – technetium tc 99m mertiatide MeSH D12.644.456.810 – teprotide MeSH D12.644.456.830 – tetragastrin MeSH D12.644.456.835 – thymic factor, circulating MeSH D12.644.456.840 – tuftsin MeSH D12.644.456.925 – vasopressins MeSH D12.644.456.925.100 – argipressin MeSH D12.644.456.925.100.250 – deamino arginine vasopressin MeSH D12.644.456.925.325 – felypressin MeSH D12.644.456.925.480 – lypressin MeSH D12.644.456.925.700 – ornipressin MeSH D12.644.456.925.730 – oxytocin MeSH D12.644.456.925.940 – vasotocin
=== Interactions with other medications === Alitretinoin must not be used concurrently with other topical medicine. Insect repellents containing DEET should not be used simultaneously with alitretinoin. Drugs that induce cytochrome P450 isoenzymes may reduce alitretinoin plasma levels.
Sources: en.wikipedia.org
Newsom came under attack from the San Francisco Democratic Party in 2009 for his failure to implement the City of San Francisco's sanctuary city rule, under which the city was to not assist U.S. Immigration and Customs Enforcement. The same year, Newsom received the Leadership for Healthy Communities Award, along with Mayor Michael Bloomberg of New York City and three other public officials, for his commitment to making healthful food and physical activity options more accessible to children and families. He hosted the Urban-Rural Roundtable in 2008 to explore ways to promote regional food development and increased access to healthy, affordable food. Newsom secured $8 million in federal and local funds for the Better Streets program, which ensures that public health perspectives are fully integrated into urban planning processes. He signed a menu-labeling bill into law, requiring that chain restaurants print nutrition information on their menus. Newsom was named "America's Most Social Mayor" in 2010 by Same Point, based on analysis of the social media profiles of mayors of the 100 largest U.S. cities.
Having broadcast on talkSPORT from 2006 to 2012, Galloway began to broadcast on talkRADIO (which launched in March 2016 as a sister station to Talksport) in June 2016. Amongst his many monologues, he said that if Scotland were to leave the UK and join the EU "it would not be a good thing for his fellow countrymen", and has condemned the BBC as a "national disgrace". In June 2019, after Liverpool Football Club had defeated Tottenham Hotspur Football Club in the Champions League final, Galloway congratulated the people of Liverpool and tweeted "No #Israël [sic] flags on the Cup!". He said that this referred to a number of Tottenham fans who were flying the flag of Israel in the crowd, showing "an affiliation to a 'racist state'". Tottenham Hotspur accused Galloway of "blatant anti-Semitism" and talkRADIO sacked him saying the broadcaster "does not tolerate anti-Semitic views".
Medea (Ancient Greek: Μήδεια, Mēdeia) is a tragedy based on a myth, written by the ancient Greek playwright Euripides. It was first performed in 431 BC as part of a trilogy, the other plays of which have not survived. Its plot centers on the actions of Medea, a former princess of the kingdom of Colchis and the wife of Jason. She finds her position in the world threatened as Jason leaves her for a princess of Corinth and takes vengeance on him by murdering his new wife, his new father-in-law, and her own two sons. She then escapes to Athens to start a new life. Euripides's play has been retold and reinterpreted for centuries. Playwrights across the world have explored it in a variety of ways, offering political, psychoanalytical, feminist, and many other original readings of Medea, Jason, and the core themes of the play. Medea, along with three other plays, earned Euripides third prize in the City Dionysia. Some believe that this indicates a poor reception, but "the competition that year was extraordinarily keen"; Sophocles, often winning first prize, came second. The play was initially rediscovered with Rome's Augustan drama, and then again in the 16th century. It has remained part of the tragedic repertoire, becoming a classic of the Western canon and the most frequently performed Greek tragedy in the 20th century. It experienced renewed interest in the feminist movement of the late 20th century, often being interpreted as a nuanced and sympathetic portrayal of Medea's struggle to take charge of her own life in a male-dominated world.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.